Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

May 24, 2021

Study Completion Date

August 30, 2021

Conditions
DyslipidemiasHigh CholesterolHypercholesterolemia
Interventions
DRUG

Obicetrapib

tablets

Trial Locations (19)

20110

Manassas Clinical Research Center, Manassas

28557

Diabetes and Endocrinology Consultants, P.C., Morehead City

31904

IACT Health, Columbus

32127

Progressive Medical Research, Port Orange

32216

Jacksonville Center for Clinical Research, Jacksonville

34474

Ocala Cardiovascular Research, Ocala

36207

Pinnacle Research Group, Anniston

44262

Summit Research Group, LLC, Munroe Falls

45227

Metabolic and Atherosclerosis Research Center, Cincinnati

46260

Midwest Institute for Clinical Research, Indianapolis

48085

Oakland Medical Research Center, Troy

57701

Monument Health Clinical Research, Rapid City

57702

Health Concepts, Rapid City

58104

Lillestol Research, LLC, Fargo

60201

Evanston Premier Healthcare Research LLC, Evanston

77040

Juno Research, LL, Houston

90057

National Research Institute - Wilshire, Los Angeles

90255

National Research Institute - Huntington Park, Huntington Park

95821

Clinical Trials Research, Sacramento

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY